Sign up to our newsletter Subscribe
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
Cell and Gene Therapies
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
No posts found